1096例儿童MASLD的长期死亡率与肝外结局:一项回顾性队列研究
该单中心回顾性队列纳入1096例2000至2017年诊断的2-18岁MASLD患儿,平均随访8.5年,总死亡率为3.4%(398/10万人年),近半数死亡与肝脏相关,肝硬化累积发生率为4.7%,肝外合并症发生率高。
要点
- 儿童MASLD患儿死亡率为398/10万人年,近半数死亡与肝脏相关。
- 男性性别和较低HDL水平独立预测死亡风险增加。
- 肝硬化累积发生率为4.7%,肝外合并症发生率高。
核心结论
- 儿童MASLD与显著的过早死亡及肝性和肝外合并症负担相关。
- 这些发现强调需要及时筛查、早期干预和长期管理策略以改善MASLD患儿结局。
研究设计与样本
- 纵向评估脂肪变性结果研究(LIVERS)是一项在Rady Children's Hospital San Diego开展的单中心回顾性队列研究。
- 纳入1096例2000至2017年诊断MASLD的2-18岁儿童,平均随访8.5年。
- 通过国家死亡指数确定死亡,通过随访研究访视和病历评估合并症。
主要发现
- 总体3.4%的儿童死亡,死亡率为398/10万人年,其中近半数死亡与肝脏相关。
- 男性性别和较低HDL水平独立预测死亡风险增加。
- 肝硬化累积发生率为4.7%。
- 肝外合并症发生率高:血脂异常3664/10万人年、高血压1901/10万人年、阻塞性睡眠呼吸暂停1185/10万人年、2型糖尿病911/10万人年。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease in children, but its long-term outcomes are poorly understood. This study aimed to quantify mortality rates, identify causes of death, and evaluate the incidence of cirrhosis and extrahepatic outcomes in children with pediatric-onset MASLD. APPROACH AND RESULTS: The Longitudinal InVestigation Evaluating Results of Steatosis (LIVERS) study is a single-center, retrospective cohort study conducted at Rady Children's Hospital San Diego. We included 1096 children aged 2-18 years who were diagnosed with MASLD between 2000 and 2017 and followed for a mean of 8.5 years. Mortality was ascertained through the National Death Index, and comorbidities were assessed through follow-up research visits and medical records. Overall, 3.4% of children died, yielding a mortality rate of 398 per 100,000 person-years; nearly half of these deaths were liver-related. Male sex and lower HDL levels independently predicted increased mortality risk. The cumulative incidence of cirrhosis was 4.7%. High incidence rates of extrahepatic comorbidities were observed, including dyslipidemia (3664 per 100,000 person-years), hypertension (1901), obstructive sleep apnea (1185), and type 2 diabetes (911). CONCLUSIONS: Pediatric MASLD is associated with significant premature mortality and a substantial burden of hepatic and extrahepatic comorbidities. These findings highlight the need for timely screening, early intervention, and long-term management strategies to improve outcomes for children with MASLD.
引用
- Schwimmer JB, Thai NQN, Noon SL, et al. Long-term mortality and extrahepatic outcomes in 1096 children with MASLD: A retrospective cohort study. Hepatology. 2025. PMID: 40262118. doi:10.1097/HEP.0000000000001357
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。